BioCare has been selected by Baxter as the exclusive, national authorized distributor for OBIZUR, the only recombinant porcine sequence factor VIII replacement treatment for acquired hemophilia A (AHA). OBIZUR was approved by the FDA for the treatment of bleeding episodes in adults with AHA, a very rare and potentially life-threatening acute bleeding disorder.

Linda Matthews, president of BioCare, said, “We appreciate Baxter’s confidence in our organization and our customer- and patient-focused approach. Our unique high-touch service model has earned BioCARE a reputation among manufacturers, hospitals, treatment centers, physicians, and patients for integrity, reliability and innovation. This is an important relationship for the treatment of AHA.”

OBIZUR is offered in single-use vials that are available in 10-vial, 5- vial and 1-vial packages and is for intravenous injection after reconstitution.

For more information about the efficacy and safety of OBIZUR, click OBIZUR_PI